Literature DB >> 23810374

Report on the first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Hong Kong SAR, China, 24-26 January 2013.

Marc P Girard1, John S Tam, Yuri Pervikov, Jacqueline M Katz.   

Abstract

On January 24-26, 2013, the World Health Organization convened the first integrated meeting on "The development and clinical trials of vaccines that induce broadly protective and long-lasting immune responses" to review the current status of development and clinical evaluation of novel influenza vaccines as well as strategies to produce and deliver vaccines in novel ways. Special attention was given to the development of possible universal influenza vaccines. Other topics that were addressed included an update on clinical trials of pandemic and seasonal influenza vaccines in high-risk groups and vaccine safety, as well as regulatory issues.
Copyright © 2013. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Adjuvants; Inactivated influenza vaccines; Live attenuated influenza vaccines; Neutralizing antibodies; Pandemic influenza vaccines; Seasonal influenza vaccines; Universal influenza vaccines

Mesh:

Substances:

Year:  2013        PMID: 23810374      PMCID: PMC9006778          DOI: 10.1016/j.vaccine.2013.06.047

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  70 in total

1.  A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection.

Authors:  Brendan M Giles; Corey J Crevar; Donald M Carter; Stephanie J Bissel; Stacey Schultz-Cherry; Clayton A Wiley; Ted M Ross
Journal:  J Infect Dis       Date:  2012-03-23       Impact factor: 5.226

2.  High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season.

Authors:  Carlos A DiazGranados; Andrew J Dunning; Emilia Jordanov; Victoria Landolfi; Martine Denis; H Keipp Talbot
Journal:  Vaccine       Date:  2012-12-20       Impact factor: 3.641

3.  Unraveling of a neutralization mechanism by two human antibodies against conserved epitopes in the globular head of H5 hemagglutinin.

Authors:  Mengran Qian; Hongxing Hu; Teng Zuo; Guiqin Wang; Linqi Zhang; Paul Zhou
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

4.  Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates.

Authors:  Filippo Ansaldi; Marta Zancolli; Paolo Durando; Emanuele Montomoli; Laura Sticchi; Giuseppe Del Giudice; Giancarlo Icardi
Journal:  Vaccine       Date:  2010-04-28       Impact factor: 3.641

5.  Characterization of the human CD8⁺ T cell response following infection with 2009 pandemic influenza H1N1 virus.

Authors:  M L B Hillaire; S E van Trierum; R Bodewes; C A van Baalen; R S van Binnendijk; M P Koopmans; R A M Fouchier; A D M E Osterhaus; G F Rimmelzwaan
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

6.  Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes.

Authors:  Taia T Wang; Gene S Tan; Rong Hai; Natalie Pica; Lily Ngai; Damian C Ekiert; Ian A Wilson; Adolfo García-Sastre; Thomas M Moran; Peter Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-18       Impact factor: 11.205

7.  A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.

Authors:  Ruth A Karron; Karen Callahan; Catherine Luke; Bhagvanji Thumar; Josephine McAuliffe; Elizabeth Schappell; Tomy Joseph; Kathleen Coelingh; Hong Jin; George Kemble; Brian R Murphy; Kanta Subbarao
Journal:  J Infect Dis       Date:  2009-03-01       Impact factor: 5.226

8.  Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies.

Authors:  Sinthujan Jegaskanda; Emma R Job; Marit Kramski; Karen Laurie; Gamze Isitman; Robert de Rose; Wendy R Winnall; Ivan Stratov; Andrew G Brooks; Patrick C Reading; Stephen J Kent
Journal:  J Immunol       Date:  2013-01-14       Impact factor: 5.422

9.  Effectiveness of maternal influenza immunization in mothers and infants.

Authors:  K Zaman; Eliza Roy; Shams E Arifeen; Mahbubur Rahman; Rubhana Raqib; Emily Wilson; Saad B Omer; Nigar S Shahid; Robert F Breiman; Robert E Breiman; Mark C Steinhoff
Journal:  N Engl J Med       Date:  2008-09-17       Impact factor: 91.245

10.  Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark.

Authors:  Björn Pasternak; Henrik Svanström; Ditte Mølgaard-Nielsen; Tyra G Krause; Hanne-Dorthe Emborg; Mads Melbye; Anders Hviid
Journal:  BMJ       Date:  2012-05-02
View more
  6 in total

1.  Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014.

Authors:  Nancy J Cox; Julian Hickling; Rebecca Jones; Guus F Rimmelzwaan; Linda C Lambert; John Boslego; Larisa Rudenko; Leena Yeolekar; James S Robertson; Joachim Hombach; Justin R Ortiz
Journal:  Vaccine       Date:  2015-10-23       Impact factor: 3.641

Review 2.  Influenza vaccines: an Asia-Pacific perspective.

Authors:  Lance C Jennings
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

Review 3.  Fast vaccine design and development based on correlates of protection (COPs).

Authors:  Cécile van Els; Siri Mjaaland; Lisbeth Næss; Julia Sarkadi; Eva Gonczol; Karen Smith Korsholm; Jon Hansen; Jørgen de Jonge; Gideon Kersten; Jennifer Warner; Amanda Semper; Corine Kruiswijk; Fredrik Oftung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans.

Authors:  Marie Borggren; Jens Nielsen; Karoline Bragstad; Ingrid Karlsson; Jesper S Krog; James A Williams; Anders Fomsgaard
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany.

Authors:  Cornelius Remschmidt; Thorsten Rieck; Birte Bödeker; Ole Wichmann
Journal:  BMC Infect Dis       Date:  2015-03-20       Impact factor: 3.090

Review 6.  Current trends in targeted therapy for drug-resistant infections.

Authors:  Leila Rahbarnia; Safar Farajnia; Behrooz Naghili; Vahideh Ahmadzadeh; Kamal Veisi; Roghayyeh Baghban; Sayna Toraby
Journal:  Appl Microbiol Biotechnol       Date:  2019-08-14       Impact factor: 4.813

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.